Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models

被引:343
作者
Amir, Eitan [1 ]
Freedman, Orit C. [1 ]
Seruga, Bostjan [1 ]
Evans, D. Gareth [2 ,3 ,4 ]
机构
[1] Princess Margaret Hosp, Div Hematol & Med Oncol, Toronto, ON M5G 2M9, Canada
[2] Univ Manchester, Med Genet Res Grp, Manchester, Lancs, England
[3] Univ Manchester, Reg Genet Serv, Manchester, Lancs, England
[4] Cent Manchester Fdn Hosp NHS Trust, Manchester, Lancs, England
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2010年 / 102卷 / 10期
关键词
GENOME-WIDE ASSOCIATION; BRCA2; MUTATION; FAMILY-HISTORY; OVARIAN-CANCER; GENETIC SUSCEPTIBILITY; PREDICTION MODELS; BOADICEA MODEL; CONFER SUSCEPTIBILITY; CARRIER PROBABILITIES; MAMMOGRAPHIC DENSITY;
D O I
10.1093/jnci/djq088
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Women who are at high risk of breast cancer can be offered more intensive surveillance or prophylactic measures, such as surgery or chemoprevention. Central to decisions regarding the level of prevention is accurate and individualized risk assessment. This review aims to distill the diverse literature and provide practicing clinicians with an overview of the available risk assessment methods. Risk assessments fall into two groups: the risk of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2 and the risk of developing breast cancer with or without such a mutation. Knowledge of breast cancer risks, taken together with the risks and benefits of the intervention, is needed to choose an appropriate disease management strategy. A number of models have been developed for assessing these risks, but independent validation of such models has produced variable results. Some models are able to predict both mutation carriage risks and breast cancer risk; however, to date, all are limited by only moderate discriminatory accuracy. Further improvements in the knowledge of how to best integrate both new risk factors and newly discovered genetic variants into these models will allow clinicians to more accurately determine which women are most likely to develop breast cancer. These steady and incremental improvements in models will need to undergo revalidation.
引用
收藏
页码:680 / 691
页数:12
相关论文
共 116 条
[51]   Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing [J].
Evans, D. G. R. ;
Lalloo, F. ;
Cramer, A. ;
Jones, E. A. ;
Knox, F. ;
Amir, E. ;
Howell, A. .
JOURNAL OF MEDICAL GENETICS, 2009, 46 (12) :811-817
[52]   Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting:: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family [J].
Evans, D. Gareth ;
Shenton, Andrew ;
Woodward, Emma ;
Lalloo, Fiona ;
Howell, Anthony ;
Maher, Eamonn R. .
BMC CANCER, 2008, 8 (1)
[53]   Breast cancer risk-assessment models [J].
Evans, D. Gareth R. ;
Howell, Anthony .
BREAST CANCER RESEARCH, 2007, 9 (05)
[54]   Cancer genetics clinics [J].
Evans, DGR ;
Cuzick, J ;
Howell, A .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (03) :391-392
[55]   A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO [J].
Evans, DGR ;
Eccles, DM ;
Rahman, N ;
Young, K ;
Bulman, M ;
Amir, E ;
Shenton, A ;
Howell, A ;
Lalloo, F .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (06) :474-480
[56]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[57]   Sequence analysis of BRCA1 and BRCA2:: Correlation of mutations with family history and ovarian cancer risk [J].
Frank, TS ;
Manley, SA ;
Olopade, OI ;
Cummings, S ;
Garber, JE ;
Bernhardt, B ;
Antman, K ;
Russo, D ;
Wood, ME ;
Mullineau, L ;
Isaacs, C ;
Peshkin, B ;
Buys, S ;
Venne, V ;
Rowley, PT ;
Loader, S ;
Offit, K ;
Robson, M ;
Hampel, H ;
Brener, D ;
Winer, EP ;
Clark, S ;
Weber, B ;
Strong, LC ;
Rieger, P ;
McClure, M ;
Ward, BE ;
Shattuck-Eidens, D ;
Oliphant, A ;
Skolnick, MH ;
Thomas, A .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2417-2425
[58]   Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2:: Analysis of 10,000 individuals [J].
Frank, TS ;
Deffenbaugh, AM ;
Reid, JE ;
Hulick, M ;
Ward, BE ;
Lingenfelter, B ;
Gumpper, KL ;
Scholl, T ;
Tavtigian, SV ;
Pruss, DR ;
Critchfield, GC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1480-1490
[59]   PROJECTING INDIVIDUALIZED PROBABILITIES OF DEVELOPING BREAST-CANCER FOR WHITE FEMALES WHO ARE BEING EXAMINED ANNUALLY [J].
GAIL, MH ;
BRINTON, LA ;
BYAR, DP ;
CORLE, DK ;
GREEN, SB ;
SCHAIRER, C ;
MULVIHILL, JJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1879-1886
[60]   A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center [J].
Gilpin, CA ;
Carson, N ;
Hunter, AGW .
CLINICAL GENETICS, 2000, 58 (04) :299-308